Core Insights - Bel Fuse (BELFB) reported quarterly earnings of $1.98 per share, exceeding the Zacks Consensus Estimate of $1.68 per share, and showing a significant improvement from a loss of $0.14 per share a year ago, resulting in an earnings surprise of +17.86% [1] - The company achieved revenues of $175.94 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.49% and increasing from $149.86 million year-over-year [2] - Bel Fuse has consistently outperformed consensus EPS and revenue estimates over the last four quarters, indicating strong operational performance [2] Earnings Outlook - The future performance of Bel Fuse's stock will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings surprise [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.56 on revenues of $162.47 million, while for the current fiscal year, the estimate is $7.35 on revenues of $714.97 million [7] Industry Context - Bel Fuse operates within the Zacks Electronics - Miscellaneous Products industry, which is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The correlation between near-term stock movements and earnings estimate revisions is strong, indicating that positive revisions could lead to further stock price appreciation [5][6]

Huntsman (HUN) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25.68%. A quarter ago, it was expected that this chemical company would post a loss of $0.13 per share when it actually produced a loss of $0.03, delivering a surprise of +76.92%.Over the last four quarters, the company has sur ...

Cadence Design Systems (CDNS) reported $1.44 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 6.2%. EPS of $1.99 for the same period compares to $1.88 a year ago.The reported revenue represents a surprise of +1.12% over the Zacks Consensus Estimate of $1.42 billion. With the consensus EPS estimate being $1.90, the EPS surprise was +4.57%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations t ...

分组1 - Medifast reported a quarterly loss of $0.55 per share, better than the Zacks Consensus Estimate of a loss of $0.76, representing an earnings surprise of +27.63% [1] - The company posted revenues of $75.1 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 6.05%, but down from $119 million year-over-year [2] - Medifast has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - Medifast shares have increased by about 0.8% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.12 on revenues of $67.12 million, and -$0.57 on revenues of $228.38 million for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Food - Miscellaneous sector is in the bottom 16% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5][6] - Medifast currently holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6]

Core Insights - Goosehead Insurance (GSHD) reported revenue of $105.26 million for the quarter ended December 2025, reflecting a 12.1% increase year-over-year and a surprise of +9.1% over the Zacks Consensus Estimate of $96.48 million [1] - The earnings per share (EPS) for the quarter was $0.64, down from $0.79 in the same quarter last year, with an EPS surprise of +18.89% compared to the consensus estimate of $0.54 [1] Revenue Breakdown - Total Core Revenue was $78.15 million, slightly above the estimated $78.08 million, representing a year-over-year increase of +15% [4] - Ancillary Revenue from Contingent Commissions reached $24.87 million, exceeding the average estimate of $16.58 million, with a year-over-year change of +3.5% [4] - Total Cost Recovery Revenue was reported at $1.77 million, above the estimated $1.72 million, marking a +14.7% increase year-over-year [4] - Total Ancillary Revenue amounted to $25.34 million, surpassing the average estimate of $16.93 million, with a year-over-year change of +3.8% [4] Key Metrics Performance - Core Revenue from Agency Fees was $2.54 million, exceeding the average estimate of $2.25 million, reflecting a +21.6% year-over-year change [4] - Ancillary Revenue from Other Franchise Revenues was $0.48 million, slightly above the estimated $0.47 million, with a +21.7% change year-over-year [4] - Initial Franchise Fees under Cost Recovery Revenue were $1.63 million, above the estimated $1.45 million, representing a +22% increase year-over-year [4] - Interest Income under Cost Recovery Revenue was $0.14 million, below the estimated $0.18 million, showing a -32.4% change year-over-year [4] - New Business Royalty Fees were reported at $7.13 million, below the estimated $7.76 million, with a +6% year-over-year change [4] - New Business Commissions reached $7.15 million, exceeding the average estimate of $6.87 million, reflecting a +19.1% year-over-year change [4] - Renewal Royalty Fees were $42.46 million, slightly above the estimated $42.1 million, with a +21.3% year-over-year change [4] - Renewal Commissions were reported at $18.88 million, below the average estimate of $19.13 million, showing a +3.9% year-over-year change [4] Stock Performance - Goosehead's shares have returned -32% over the past month, compared to a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $1.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +28.57%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.33, delivering a surprise of +26.67%.Over the last four quarters, the company has su ...

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.77%. A quarter ago, it was expected that this medical device maker would post earnings of $0.16 per share when it actually produced earnings of $0.36, delivering a surprise of +125%.Over the last four ...

USANA Health Sciences (USNA) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +46.34%. A quarter ago, it was expected that this nutritional supplement maker would post a loss of $0.15 per share when it actually produced a loss of $0.15, delivering no surprise.Over the last four quarters ...

Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.47%. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.27 per share when it actually produced a loss of $0.16, delivering a surprise of +40.74%.Over the last four quarters, the com ...

Core Viewpoint - Expand Energy (EXE) reported quarterly earnings of $2 per share, exceeding the Zacks Consensus Estimate of $1.89 per share, and showing significant growth from $0.55 per share a year ago, indicating strong performance in the oil and gas sector [1] Financial Performance - The company achieved revenues of $2.31 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.56%, and up from $1.6 billion in the same quarter last year [2] - Over the last four quarters, Expand Energy has exceeded consensus EPS estimates three times and topped revenue estimates two times [2] Stock Performance - Expand Energy shares have declined approximately 5.7% since the beginning of the year, contrasting with the S&P 500's slight decline of 0.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.34 on revenues of $2.46 billion, and for the current fiscal year, it is $8.19 on revenues of $9.43 billion [7] - The trend of earnings estimate revisions for Expand Energy was mixed prior to the earnings release, which may influence future stock performance [6] Industry Context - The Alternative Energy - Other industry, to which Expand Energy belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]